Showing results (971-980 of 3,351) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|February 8, 2000
Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemiaP Y Cremieux, S N Finkelstein, E R Berndt, et al.Pharmacoeconomics|January 6, 2000
Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcerM Tavakoli, A T Prach, M Malek, et al.Pharmacoeconomics|January 6, 2000
Economic evaluation of the treatment of chronic wounds: hydroactive wound dressings in combination with enzymatic ointment versus gauze dressings in patients with pressure ulcer and venous leg ulcer in GermanyR Bergemann, K W Lauterbach, W Vanscheidt, et al.Pharmacoeconomics|January 6, 2000
Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UKM Nuijten, L Meester, F Waibel, et al.Pharmacoeconomics|January 6, 2000
Costs associated with symptomatic systolic heart failureP G Davey, P B Clarkson, A McMahon, et al.Pharmacoeconomics|January 6, 2000
Influenza vaccination in 29 countries. An update to 1997F Ambrosch, D S FedsonPharmacoeconomics|January 6, 2000
Willingness to pay and the valuation of programmes for the prevention and control of influenzaS Birch, A Gafni, B O'BrienPharmacoeconomics|December 8, 1997
Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in FranceP Boyer, J M Danion, J C Bisserbe, et al.Pharmacoeconomics|October 5, 1995
Cost effectiveness of antituberculosis interventionsA Castelo, P A Mathiasi, R Iunes, et al.Pharmacoeconomics|November 4, 1995
Economic and quality-of-life impact of NSAIDs in rheumatoid arthritis: A conceptual framework and selected literature reviewS E Gabriel, E L MattesonPageof 336